Please assess the completion status of the following clinical trial:

Trial Title: 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 13-18 years~* English-speaking~* DSM diagnoses that have an FDA indication for SGA use for at least one agent in the respective pediatric or adult age group. Specifically, primary DSM-IV diagnosis of early-onset schizophrenia spectrum disorders; bipolar I disorder mania (and BP-NOS); irritability associated with autism spectrum disorder, as well as severe mood dysregulation (SMD) according to Leibenluft et al. (2011) with an ABC-irritability score of \>/=18 Sexually active girls must agree to use two effective forms of birth control or be abstinent~* Participant has a primary caretaker who has known the child well for at least 6 months before study entry Primary caretaker is able to participate in study appointments~* Ability of child to participate in all aspects of the protocol per investigator clinical judgment.~Exclusion Criteria:~* Major neurological or medical illnesses that affect weight (e.g., unstable thyroid disease), require a prohibited systemic medication (e.g., diabetes mellitus \[insulin\], chronic renal failure \[steroids); Fasting glucose \> 125 mg/dL on 2 occasions during screening~* Any medication (other than currently prescribed psychotropic medications) that would significantly alter weight~* Antidepressants not allowed for at least 2 weeks in BP-I or BP-NOS patients~* DSM-IV diagnosis of anorexia or bulimia nervosa~* DSM-IV diagnosis of Substance Dependence disorder (other than tobacco dependence) within the past month~* Initial urine toxicology screen and follow-up screen indicate ongoing use of illicit substance~* Hypersensitivity to ZIP or UC antipsychotics~* Pregnant, breast feeding or unwilling to comply with contraceptive requirements~* Screening or baseline QTc \> 450 msec~* IQ \< 55~* Significant risk for dangerousness to self or to others~* Ongoing or previously undisclosed child abuse requiring new department of social service intervention.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Ziprasidone (Type: ACTIVE_COMPARATOR): (20-160mg/d, bid) for 12 weeks
- Aripiprazole, quetiapine, risperidone (Type: ACTIVE_COMPARATOR): Aripiprazole (2-30mg/d), Quetiapine (25-800mg/d) or Risperidone (0.1-8mg/d) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).